Metraipolis › archive › dc_3e29eb8762b8

Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors — Europe PMC PMID:42422566

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42422566
DOI
10.1093/ckj/sfag181
License (as archived)
solo-consultazione
Archived
2026-10-31T21:04:50.647Z
SHA-256 of the archived text
c97bfa47dc5c97b26f764ebc48e739bea4c95e59b6d13064b2dd351230016996
Stable URL of this page
https://metraipolis.com/documento/dc_3e29eb8762b8

How to cite

Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors — Europe PMC PMID:42422566 — Europe PMC (en), https://europepmc.org/article/MED/42422566 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3e29eb8762b8 (Metraipolis archive dc_3e29eb8762b8, sha256 c97bfa47dc5c97b26f764ebc48e739bea4c95e59b6d13064b2dd351230016996)
BibTeX
@misc{dc3e29eb8762b8,
  title = {Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors — Europe PMC PMID:42422566},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42422566},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3e29eb8762b8; sha256 c97bfa47dc5c97b26f764ebc48e739bea4c95e59b6d13064b2dd351230016996},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42422566. Agents can read the archived copy with the MCP tool read_document.